Goldman Sachs
NBRV

Goldman Sachs’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Goldman Sachs’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-226
Closed -$30K – 5854
2020
Q3 		$30K Buy
226
+174
+335% +$29.1K ﹤0.01% 5231
2020
Q2 		$9K Sell
52
-425
-89% -$70.9K ﹤0.01% 5150
2020
Q1 		$69K Buy
+477
New +$146K ﹤0.01% 4997
2019
Q2 		– Sell
-536
Closed -$327K – 5451
2019
Q1 		$327K Buy
536
+446
+496% +$243K ﹤0.01% 4593
2018
Q4 		$33K Sell
90
-192
-68% -$103K ﹤0.01% 5123
2018
Q3 		$190K Sell
282
-76
-21% -$53.9K ﹤0.01% 4938
2018
Q2 		$312K Buy
358
+55
+18% +$63K ﹤0.01% 4763
2018
Q1 		$381K Sell
303
-123
-29% -$182K ﹤0.01% 4658
2017
Q4 		$637K Buy
+426
New +$674K ﹤0.01% 4635

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Goldman Sachs's NBRV Position: Q4 2020 in Review

Goldman Sachs sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2020, closing a stake of 226 shares — an estimated $30K sold.

Goldman Sachs first reported a position in NBRV in Q4 2017 and held it in 9 quarters. The position peaked at $637K in Q4 2017. 33 funds tracked by Wall St. Rank hold NBRV as of Q4 2020.

  • Goldman Sachs reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2020 after selling out during the quarter.
  • Goldman Sachs sold 226 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2020, an estimated $30K.
  • Goldman Sachs first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2017 and held it in 9 quarters.
  • Goldman Sachs's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $637K in Q4 2017.
  • 33 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2020.

Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.